Peritoneal adhesion prevention at cesarean section: an analysis of the effectiveness of an absorbable adhesion barrier.

Objective: To evaluate the effectiveness of an absorbable adhesion barrier utilized at cesarean delivery.

Study Design: We performed a retrospective, two-arm cohort, chart review of primary and subsequent first repeat cesarean sections from January 1, 2006-December 31, 2009. Exclusion criteria were incomplete operative report, history of prior abdominal-pelvic surgery, pelvic inflammatory disease, chorioamnionitis, emergency cesarean delivery or use of corticosteroids within 2 weeks.

One patient, two uteri, two endometrial ablations: case report of thermal balloon ablation in uterine didelphys.

Objective: To describe the clinical application and outcomes after endometrial ablation with ThermachoiceIII (Ethicon, Somerville, NJ) in a patient with uterine didelphys with heavy menstrual bleeding.

Design: Case report.

Setting: Inner-city community obstetrics and gynecology clinic.

Emergent thermal balloon ablation for acute uterine hemorrhage: a report of 2 cases.

Background: The management of acute, recalcitrant uterine hemorrhage has traditionally included gynecologic dilation and curettage, uterine balloon tamponade or emergent hysterectomy. These options were considered after failed medical therapy (intravenous estrogen, oral contraceptives or intramuscular progestins). The advent of global endometrial ablation devices now allow for an in-office treatment modality for these patients.

Ketorolac-mepivacaine lower uterine block for in-office endometrial ablation: a randomized, controlled trial.

Objective: To investigate the effectiveness of a nonsteroidal antiinflammatory drug (NSAID) administered in combination with a local anesthetic as a deep paracervical block for in-office endometrial ablations.

Study Design: Double-blind, placebo-controlled, randomized trial. Patients received either sublingual ketorolac (30 mg/1 mL) or a mepivacaine-only paracervical injection (standard group) or received sublingual saline (1 mL) and a ketorolac (30 mg/1 mL)-mepivacaine paracervical block (NSAID group)for Gynecare Thermachoice III ablation (Ethicon, Inc.

In-office endometrial ablation using a third-generation uterine balloon therapy system: 12-month prospective follow-up on menstrual patterns and dysmenorrhea impact.

Objective: To evaluate the efficiency of in-office Thermachoice III (Ethicon, Somerville, New Jersey) endometrial ablations in resolving menstrual abnormalities as well as dysmenorrhea at 12 months after the procedure.

Study Design: This was a prospective, single arm, cohort study of women from an inner city, community based, physician group medical/ surgical clinic. Diagnostic hysteroscopy, dilation and curettage, and Thermachoice III endometrial ablation were performed under local analgesia.

In-office thermachoice III ablation: a comparison of two anesthetic techniques.

Background: Patient comfort and safety are prerequisites for office procedures.

Study Objective: comparison of the fentanyl transdermal patch with injection of local anesthesia for intraoperative/postoperative pain from in-office Thermachoice III ablations.

Methods: Single-center prospective randomized (1:1) cohort study.

In-office endometrial ablation and clinical correlation of reduced menstrual blood loss and effects on dysmenorrhea and premenstrual symptomatology.

Objective: To evaluate in-office Thermachoice III endometrial ablation on subsequent dysmenorrhea and premenstrual mood symptoms in relation to decreased menstrual blood loss.

Study Design: The study conducted was in a prospective cohort single group. Ablations were performed on 148 patients under parametrial block using dilute mepivacaine and oral anxiolysis for a diagnosis of menorrhagia.